Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.

09/25/2026, 6:05 AM • The Motley Fool

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

09/24/2026, 1:00 PM • GlobeNewswire

InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

InnoCare Pharma has entered into a strategic research collaboration and license agreement with Eli Lilly to discover and develop compounds against up to five targets. Under the agreement, InnoCare is eligible to receive up to $100 million in upfront and near-term payments, plus up to $3.25 billion in development and commercial milestone payments, along with single-digit tiered royalties on net product sales.

09/24/2026, 12:20 AM • GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HUTCHMED announced that two Phase III studies evaluating the savolitinib and osimertinib combination for non-small cell lung cancer will be presented at ESMO Congress 2026 in Madrid. The SAFFRON global study and SANOVO China study both demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared to chemotherapy and osimertinib monotherapy, respectively. The all-oral, chemo-free combination has been selected for high-profile oral presentations including a Presidential Symposium.

09/23/2026, 8:00 PM • GlobeNewswire

Why Viking Therapeutics Stock Skyrocketed on Tuesday

Viking Therapeutics' stock surged 35.67% after announcing positive clinical trial results for its obesity drug VK2735. Participants lost 16-19% of body weight over 21 weeks and maintained up to 97% of weight loss with flexible dosing schedules. The drug showed strong tolerability with low discontinuation rates, positioning Viking as a potential challenger in the rapidly expanding obesity drug market projected to reach $150 billion by 2035.

09/23/2026, 12:04 AM • The Motley Fool

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

09/22/2026, 10:04 PM • The Motley Fool

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems

Novo Nordisk is rebranding to 'Novo' as it launches a pill version of its GLP-1 weight-loss drug to regain market share lost to Eli Lilly. While the company has a solid strategy with low pricing to drive volume, the name change alone won't address fundamental competitive challenges. The stock is down 70% from its 2024 high, though it trades at an attractive valuation with a 4.1% dividend yield.

09/22/2026, 4:15 PM • The Motley Fool

Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study

Roche reported positive Phase II results for enicepatide, its once-weekly dual GLP-1/GIP receptor agonist, showing dose-dependent HbA1c reductions of 2.65% and body weight loss of 15.5% at the 24 mg dose in type 2 diabetes patients. The drug was well-tolerated with minimal discontinuations. Roche is advancing two Phase III weight-management studies and plans to initiate Phase III glycemic-control and cardiovascular trials in H1 2027, positioning itself to compete in the growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk.

09/22/2026, 3:32 PM • Zacks

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.

09/22/2026, 12:02 PM • The Motley Fool

Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know

Eli Lilly closed at $1,164.89, up 1.04% but underperforming the S&P 500's 1.49% gain. The stock declined 8.16% over the past month, trailing the broader market. Analysts expect strong earnings growth of 36.18% YoY with revenue projected at $22.08 billion (+25.46%), but the company trades at a premium valuation with a Forward P/E of 31.94 versus the industry average of 15.87. Eli Lilly holds a Zacks Rank #3 (Hold) rating.

09/21/2026, 5:45 PM • Zacks

Why Twist Bioscience Stock Skyrocketed This Week

Twist Bioscience stock surged over 31% this week after announcing a partnership with Eli Lilly to participate in Lilly TuneLab, an AI-powered drug discovery initiative. Twist will provide antibody characterization data services and leverage its AbLab model, generating revenue while contributing to and benefiting from the advanced research platform.

09/18/2026, 7:36 PM • The Motley Fool

Better Buy for Cautious Investors: Eli Lilly vs Costco

The article compares Eli Lilly and Costco as defensive stock picks for cautious investors amid market hesitation. Eli Lilly benefits from its dominant GLP-1 weight loss drug portfolio (Mounjaro and Zepbound), while Costco offers stability through its membership-based business model with high renewal rates. Despite both stocks being reasonably valued, the author recommends Costco as the better buy, trading at approximately 39x forward earnings compared to Eli Lilly's historical valuation levels.

09/18/2026, 10:15 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

This Trend is Excellent News for Eli Lilly and Its Investors

Eli Lilly dominates the weight loss drug market with 60% U.S. share and is gaining ground in the new oral GLP-1 pill segment. While Novo Nordisk's Wegovy pill currently leads in prescriptions (183,000 vs. 47,500 for Lilly's Foundayo), the gap is narrowing—mirroring Lilly's previous dominance shift in injectable GLP-1 drugs. Lilly's Foundayo offers convenience advantages, and analysts project the weight loss drug market to reach $100 billion by decade's end.

09/17/2026, 4:15 AM • The Motley Fool

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

09/15/2026, 6:40 AM • GlobeNewswire